Correlation with overall survival of response rate (RR) and disease control rate (DCR) in phase II randomized controlled trials evaluating second- or later-line chemotherapy for advanced, locally advanced, and recurrent non-small cell lung cancer. - Correlation with overall survival of response rate (RR) and disease control rate (DCR) in phase II randomized controlled trials evaluating second- or later-line chemotherapy for advanced, locally advanced, and recurrent non-small cell lung cancer.

Yokohama City University0 sites9,059 target enrollmentMay 15, 2020

ConditionsSCLC

Overview

Please see: Transl Lung Cancer Res. 2021 May;10(5):2278-2289. doi: 10.21037/tlcr-20-1120.

Registry

who.int

Start Date

May 15, 2020

End Date

May 15, 2021

Last Updated

2 years ago

Study Type

Others,meta-analysis etc

Sex

All

Sponsor

•Study Selection: study design We will include phase II RCTs that evaluate second\- or later\-line chemotherapy for advanced, locally advanced, and recurrent NSCLC. Articles need to be written up as full articles, brief reports, or conference abstracts regardless of their primary end point. Non\-English language reports will be excluded. A phase I/II trial will be allowed. A phase II/III trial will be included when data from phase II part can be extractable Study selection: treatment The interventions include cytotoxic agents, molecular targeted therapies, immune checkpoint inhibitors, and their combinations. Immunotherapy other than immune checkpoint inhibitors will not be included because such treatment is not current standard. Comparison of the same drugs in the form of low\-dose versus high\-dose or weekly versus 3\-weekly regimens will be allowed. Maintenance therapy after the first\-line chemotherapy will not considered as the second\-line treatment.